Invitation to presentation of BioArctic’s fourth quarter report for October – December 2025 on February 18 at 9.30 a.m. CET February 11, 2026 08:30 Non Regulatory Read more
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China February 9, 2026 06:45 Regulatory Read more
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025 February 6, 2026 12:00 Regulatory Read more
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab) January 26, 2026 22:00 Regulatory Read more
Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA January 26, 2026 00:30 Regulatory Read more
BLA for subcutaneous formulation of Leqembi® accepted in China January 6, 2026 12:00 Regulatory Read more
